Asset Type: Brochures, Discovery, Radiopharmaceutical Services, RLT, Radiopharmaceutical 
Therapy & Theranostics

Discovery to Dose™: Connecting Radiopharmaceutical Discovery with Clinical Manufacturing

Discovery to Dose™: Connecting Radiopharmaceutical Discovery with Clinical Manufacturing

A coordinated development pathway from early target validation through clinical and commercial manufacturing.

Radiopharmaceutical development requires close alignment between discovery research, translational science, CMC development, and GMP manufacturing. When these activities are disconnected, sponsors can face challenges with data continuity, process development, and clinical readiness.

Through Discovery to Dose™, Perceptive Discovery and Nucleus RadioPharma connect complementary scientific and manufacturing expertise to help radiopharmaceutical developers anticipate challenges earlier and make informed decisions throughout development.

What You’ll Learn

Download our Discovery to Dose™ flyer to explore:

  • Integrated development planning: Connecting early target validation, radiochemistry, preclinical studies, and manufacturing considerations.
  • Preclinical radiopharmaceutical development: Perceptive Discovery’s capabilities in molecular imaging, biodistribution, efficacy, and dosimetry.
  • CMC and manufacturing expertise: Nucleus RadioPharma’s capabilities in process development, analytical methods, and GMP manufacturing.
  • Clinical translation: Coordinating scientific, manufacturing, and regulatory considerations to support IND readiness.
  • Flexible partnership structure: A non-exclusive model that allows sponsors to engage either organization independently or access coordinated support.

Discover how aligning development and manufacturing expertise earlier can help reduce development friction and preserve scientific continuity.

Logo

Building a Strong Foundation for Radioligand Therapy Development

Successful radioligand therapy programs begin with robust preclinical characterization. Perceptive Discovery provides radiochemistry, in vitro and in vivo research, quantitative imaging, biodistribution, efficacy, and dosimetry services to generate the evidence needed to support development decisions.

Through Discovery to Dose™, these insights can inform downstream CMC planning and manufacturing activities.